STOCK TITAN
  1. Home
  2. Sec-filings
  3. TBPH
  4. [Form 4] Theravance Biopharma, Inc. Insider Trading Activity

Theravance Biopharma (NASDAQ: TBPH) SVP has 5,667 shares withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) reported that officer Rhonda Farnum, SVP, Commercial & Medical Affairs, had 5,667 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations from the vesting of previously granted restricted stock units. The withholding was with the issuer and did not involve an open market transaction, leaving her with 226,790 shares held directly.

Positive

  • None.

Negative

  • None.
Insider Farnum Rhonda
Role SVP, COMM & MEDICAL AFFAIRS
Type Security Shares Price Value
Tax Withholding Ordinary Shares F1 5,667 $16.95 $96K
Holdings After Transaction: Ordinary Shares — 226,790 shares (Direct)
Footnotes (1)
  1. F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Shares withheld for taxes 5,667 shares Ordinary Shares withheld on 2026-08-20 for tax obligations on RSU vesting
Withholding reference price $16.95 per share Value used for the 5,667-share tax-withholding transaction
Shares held after transaction 226,790 shares Directly owned Ordinary Shares following the 2026-08-20 withholding
restricted stock units financial
"arising out of the vesting of previously granted restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
withheld to satisfy tax obligations financial
"Shares withheld to satisfy tax obligations arising out of the vesting"
open market transaction financial
"did not involve an open market transaction"
An open market transaction is a buy or sell of publicly traded securities executed on an exchange or other public trading venue where many buyers and sellers can participate. It matters to investors because these trades change the visible supply and demand for a stock—like shoppers moving prices in a busy marketplace—affecting share price, liquidity (how easily you can trade), and sometimes the balance of ownership.

FAQ

What insider transaction did TBPH officer Rhonda Farnum report on this Form 4?
She reported that 5,667 Ordinary Shares of Theravance Biopharma, Inc. were withheld on 2026-08-20 to satisfy tax obligations from the vesting of previously granted restricted stock units, in a transaction with the issuer rather than in the open market.

Was the TBPH Form 4 transaction an open market sale of shares?
No. The filing states the share withholding transaction was with the issuer and did not involve an open market transaction, and was done to cover tax obligations arising from the vesting of restricted stock units.

How many TBPH shares were withheld for taxes in Rhonda Farnum’s Form 4?
The Form 4 reports that 5,667 Ordinary Shares of Theravance Biopharma, Inc. were withheld at a reported value of $16.95 per share to satisfy tax obligations related to vesting restricted stock units.

How many TBPH shares does Rhonda Farnum hold after the reported transaction?
After the tax-withholding transaction, Rhonda Farnum is reported to hold 226,790 Ordinary Shares of Theravance Biopharma, Inc. directly.

What does transaction code F mean in the TBPH Form 4 filing?
Transaction code F in the filing is described as payment of tax liability by delivering or withholding securities, here referring to shares withheld to cover taxes from vesting restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farnum Rhonda
(Last)(First)(Middle)
C/O THERAVANCE BIOPHARMA US, LLC
901 GATEWAY BLVD
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, COMM & MEDICAL AFFAIRS
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares08/20/2026F5,667(1)D$16.95226,790D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
/s/ Brett A Grimaud, Attorney-in-Fact08/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR